The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: Their learning and development programs.
A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
The conference highlights the convergence of digital health and drug development. Among the panel discussions are a focus on the state of AI in drug discovery and the future of digital medicines. A startup pitch contest spotlights companies seeking to improve clinical trials. Register for free today!
Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.